BriaCell Therapeutics Corp. Warrant expiring 2031
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that… Read more
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) - Net Assets
Latest net assets as of : $- USD
Based on the latest financial reports, BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) has net assets worth $- USD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($-) and total liabilities ($-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
BriaCell Therapeutics Corp. Warrant expiring 2031 - Net Assets Trend (None–None)
This chart illustrates how BriaCell Therapeutics Corp. Warrant expiring 2031's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BriaCell Therapeutics Corp. Warrant expiring 2031 (None–None)
The table below shows the annual net assets of BriaCell Therapeutics Corp. Warrant expiring 2031 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to BriaCell Therapeutics Corp. Warrant expiring 2031's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
BriaCell Therapeutics Corp. Warrant expiring 2031 Competitors by Market Cap
The table below lists competitors of BriaCell Therapeutics Corp. Warrant expiring 2031 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Basin Uranium Corp
PINK:BURCF
|
$2.00 Million |
|
AJ Greentech Holdings Ltd
PINK:SUIC
|
$2.00 Million |
|
Pegasus Resources Inc
PINK:SLTFF
|
$2.00 Million |
|
Multi-Usage Holdings Bhd
KLSE:9539
|
$2.00 Million |
|
Rogue Resources Inc
PINK:GCRIF
|
$2.00 Million |
|
Iconic Minerals Ltd.
OTCQB:ICMFF
|
$2.00 Million |
|
VPR Brands LP
PINK:VPRB
|
$2.00 Million |
|
Bradda Head Lithium Limited
PINK:BHLIF
|
$2.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BriaCell Therapeutics Corp. Warrant expiring 2031's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares BriaCell Therapeutics Corp. Warrant expiring 2031's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BriaCell Therapeutics Corp. Warrant expiring 2031 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares BriaCell Therapeutics Corp. Warrant expiring 2031's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) | $- | N/A | N/A | $2.00 Million |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |